09.12.2012 Views

scientific program • symposia - American Society for Reproductive ...

scientific program • symposia - American Society for Reproductive ...

scientific program • symposia - American Society for Reproductive ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Short and Simple<br />

Short: Mean duration of treatment — 5.4 days 1*<br />

Simple: Only GnRH antagonist available in a<br />

ready-to-use pre-fi lled syringe 1<br />

<strong>•</strong> Rapidly absorbed —<br />

approximately 1 hour after dosing 1<br />

<strong>•</strong> Rapidly reversible —<br />

within 48 hours of discontinuation,<br />

pituitary hormones (LH and FSH)<br />

are fully recovered 1<br />

<strong>•</strong> Small injection volume – 0.5 mL 1<br />

<strong>•</strong> Room temperature storage 1<br />

*Results from a multicenter, open-label randomized study to assess the effi cacy and safety of<br />

Ganirelix Acetate Injection in women undergoing controlled ovarian hyperstimulation. Range 2-14 days.<br />

Ganirelix Acetate Injection is indicated <strong>for</strong> the inhibition of premature LH surges in women undergoing controlled<br />

ovarian hyperstimulation.<br />

SELECTED SAFETY INFORMATION<br />

<strong>•</strong> Ganirelix Acetate Injection is contraindicated in patients with a known hypersensitivity to Ganirelix Acetate or to any<br />

of its components, to GnRH or any other GnRH analog, and in patients with known or suspected pregnancy.<br />

<strong>•</strong> Only physicians experienced in infertility treatment should prescribe Ganirelix Acetate Injection. Be<strong>for</strong>e starting<br />

treatment with Ganirelix, pregnancy must be excluded.<br />

<strong>•</strong> Cases of hypersensitivity reactions, including anaphylactoid reactions with the fi rst dose, have been reported during<br />

post-marketing surveillance. The packaging of this product contains natural rubber latex which may cause<br />

allergic reactions.<br />

<strong>•</strong> The most common adverse events occurring in ≥1% of patients treated with Ganirelix in clinical trials (N=794) include:<br />

abdominal pain (gynecological) 4.8%, fetal death 3.7%, headache 3.0%, ovarian hyperstimulation syndrome (OHSS)<br />

2.4%, vaginal bleeding 1.8%, injection site reaction 1.1%, nausea 1.1%, abdominal pain (gastrointestinal) 1.0%.<br />

Please see adjacent page <strong>for</strong> brief summary of full Prescribing In<strong>for</strong>mation.<br />

Reference: 1. Ganirelix Acetate Injection [package insert]. Roseland NJ: Organon USA Inc.<br />

Copyright © 2010, N.V. Organon, a subsidiary of Merck & Co., Inc. All rights reserved. Printed in USA. GX2046 8/10

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!